The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody (Q36150505)

12 August 2017

1 reference

title

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody (English)

1 reference

12 August 2017

1 reference

Masahiko Mihara

1

1 reference

12 August 2017

Norihiro Nishimoto

series ordinal

2

1 reference

12 August 2017

Yoshiyuki Ohsugi

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

5

1 reference

12 August 2017

683-690

1 reference

The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Interleukin 6 is required for the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Urinary IL-6: a marker for mesangial proliferative glomerulonephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Interleukin-6 is elevated in plasma in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB × NZW)F1 hybrid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.683

21 January 2018

Identifiers

DOI

10.1517/14712598.5.5.683

1 reference

12 August 2017

1 reference